How does 950's PE Ratio compare to its peers?

950 is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the peer average (7.9x).

How does 950's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

950 is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the Hong Kong Pharmaceuticals industry average (8.4x).

What is 950's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 950's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 950 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

950 (HK$1.23) is trading above our estimate of [[fair value]] (HK$0.66)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Lee's Pharmaceutical Holdings (SEHK:950) - Stock Price, News & Analysis

950 Stock Overview

An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. More details

950 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	4/6
Financial Health	5/6
Dividends	1/6

Rewards

Earnings grew by 61.9% over the past year

Risk Analysis

Earnings have declined by 14.9% per year over past 5 years

Does not have a meaningful market cap (HK$724M)

Lee's Pharmaceutical Holdings Limited Competitors

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$803.1m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$767.5m

Pak Fah Yeow International

SEHK:239

HK$760.4m

Price History & Performance

Summary of all time highs, changes and price drops for Lee's Pharmaceutical Holdings
Historical stock prices
Current Share Price	HK$1.23
52 Week High	HK$1.75
52 Week Low	HK$1.00
Beta	0.87
11 Month Change	-2.38%
3 Month Change	0%
1 Year Change	-7.52%
33 Year Change	-64.66%
5 Year Change	-69.70%
Change since IPO	136.54%

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Shareholder Returns

	950	HK Pharmaceuticals	HK Market
7D	-3.9%	0.8%	0.4%
1Y	-7.5%	-7.5%	12.0%

Return vs Industry: 950 matched the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.

Return vs Market: 950 underperformed the Hong Kong Market which returned 12% over the past year.

Price Volatility

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stable Share Price: 950 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 950's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	993	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments.

Lee's Pharmaceutical Holdings Limited Fundamentals Summary

How do Lee's Pharmaceutical Holdings's earnings and revenue compare to its market cap?
950 fundamental statistics
Market cap	HK$724.27m
Earnings (TTM)	HK$63.06m
Revenue (TTM)	HK$1.20b

11.5x

P/E Ratio

0.6x

P/S Ratio

Is 950 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
950 income statement (TTM)
Revenue	HK$1.20b
Cost of Revenue	HK$581.63m
Gross Profit	HK$617.44m
Other Expenses	HK$554.38m
Earnings	HK$63.06m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	51.49%
Net Profit Margin	5.26%
Debt/Equity Ratio	14.2%

How did 950 perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

28%

Payout Ratio

950 Stock Overview

Rewards

Risk Analysis

Lee's Pharmaceutical Holdings Limited Competitors

SEHK:503

HK$750.6m

SEHK:3737

HK$803.1m

SEHK:8049

HK$767.5m

SEHK:239

HK$760.4m

Price History & Performance

Recent News & Updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022